Knee OsteoArthritis (KOA) is a common disease associated with pain and impaired function. Many patients are not relieved of their symptoms with enough efficacy by conservative treatments. Genicular Arteries Embolization (GAE) is a new minimally invasive endovascular treatment allowing symptoms relief. The investigator previously demonstrated the safety of GAE using an ethiodized oil-based emulsion for the treatment of painful knee osteoarthritis in a first-in-man single-arm clinical trial called LipioJoint-1 (clinicaltrials.gov: NCT04733092; EUDRACT: 2020-002206-10). This phase 1 study also provided encouraging evidence of GAE efficacy on knee pain and function.
The purpose of LipioJoint-2 study is to assess GAE efficacy using an ethiodized oil-based emulsion for the treatment of painful knee osteoarthritis in a multicenter, prospective, randomized sham-controlled clinical trial.

Start Date30 Sep 2024

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

NCT05842174 / Not yet recruitingPhase 1/2IIT

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma Through Image-guided Locoregional Therapy

Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemotherapeutics and then blocking the artery with embolics in order to kill tumor cells by depriving them of essential oxygen and nutrients. While TACE has a proven survival benefit, local recurrence is common, and long-term survival rates are poor. Prior studies demonstrate that HCC cells survive the oxygen and nutrient deprivation through autophagy, a process of cellular self-eating, to provide nutrients required for survival. The proposed project will leverage this dependency to develop a novel approach to TACE that integrates autophagy inhibition to improve therapeutic response by increasing tumor cell killing and enhancing anti-tumor immunity.

Start Date01 Jul 2024

Sponsor / Collaborator

VA Office of Research and Development

NCT05490381 / WithdrawnPhase 1IIT

Super-Selective Intra-Arterial Embolization of Hypervascular Head and Neck Tumors

This phase I trial tests whether embolization done prior to surgery (preoperative) will improve surgical outcomes in head and neck tumors with large amounts of blood vessels (hypervascular). Embolization is a minimally invasive surgical technique performed under angiographic (imaging of blood vessels) guidance. Embolization therapy injects tiny particles into the arteries feeding tumors to cut off their blood supply which may help improve outcomes by preventing blood loss during surgery, reducing surgical times, and shrinking tumors or reducing recurrence.

Start Date21 Dec 2023

Sponsor / Collaborator

University of Washington

[+1]

100 Clinical Results associated with Ethiodized Oil

100 Translational Medicine associated with Ethiodized Oil

100 Patents (Medical) associated with Ethiodized Oil

2,402

Literatures (Medical) associated with Ethiodized Oil

01 Dec 2024·ACADEMIC RADIOLOGY

Lipiodol Combined with Drug-eluting Beads Versus Drug-eluting Beads Alone for Transarterial Chemoembolization of Hepatocellular carcinoma: A Multicenter Study

Article

Author: Liang, Zhiying ; Ji, Kun ; Zhou, Guanhui ; Ai, Jing ; Jing, Li ; Zhu, Jinghua ; Chen, Feng ; Cao, Yunbo ; Niu, Jiahua ; Zhang, Cong ; Xu, Tiantian ; Cao, Shoujin ; Shi, Yang ; Li, Zhen

RATIONALE AND OBJECTIVES:

This study aimed to propose a novel approach of lipiodol combined with drug-eluting beads transarterial chemoembolization (Lipiodol-DEB TACE) and to compare the safety and efficacy with DEB-TACE alone for patients with unresectable hepatocellular carcinoma (HCC).

MATERIALS AND METHODS:

From the database of four centers, the records of patients with HCC who received DEB-TACE or Lipiodol-DEB TACE as initial treatment were retrospectively evaluated. The tumor response was measured based on the Modified Response Evaluation Criteria in Solid Tumors. Overall survival (OS), progression-free survival (PFS) and adverse events (AEs) were compared between two groups.

RESULTS:

A total of 244 patients were included with 160 patients receiving DEB-TACE and 84 patients receiving Lipiodol-DEB TACE. Lipiodol-DEB TACE group had higher objective response rate (86.9 % vs. 76.3 %), higher disease control rate (97.6 % vs. 88.8 %), longer median OS (42.6 vs. 25.8 months) and longer median PFS (34.0 vs. 17.0 months) than DEB-TACE group (P < 0.05). There was no significant difference observed in the incidence of AEs between two groups. Cox analysis identified total bilirubin level, maximum tumor diameter, TACE method and portal vein invasion as independent prognostic factors.

CONCLUSION:

Lipiodol-DEB TACE was a safe option and associated with improved tumor response and survival outcome compared to DEB-TACE alone for selected patients with HCC.

01 Nov 2024·CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY

Creation of a Prediction Model of Local Tumor Recurrence After a Successful Conventional Transcatheter Arterial Chemoembolization Using Cone-Beam Computed Tomography Based–Radiomics

Article

Author: Haraguchi, Takafumi ; Wada, Shinji ; Mimura, Hidefumi ; Nishio, Misako ; Nawata, Shintaro ; Hashimoto, Kazuki ; Hamaguchi, Shingo

PURPOSE:

To create and evaluate prediction models of local tumor recurrence after successful conventional transcatheter arterial chemoembolization (c-TACE) via radiomics analysis of lipiodol deposition using cone-beam computed tomography (CBCT) images obtained at the completion of TACE.

MATERIALS AND METHODS:

A total of 103 hepatocellular carcinoma nodules in 71 patients, who achieved a complete response (CR) based on the modified Response Evaluation Criteria in Solid Tumors 1 month after TACE, were categorized into two groups: prolonged CR and recurrence groups. Three types of areas were segmented on CBCT: whole segment (WS), tumor segment (TS), and peritumor segment (PS). From each segment, 105 radiomic features were extracted. The nodules were randomly divided into training and test datasets at a ratio of 7:3. Following feature reduction for each segment, three models (clinical, radiomics, and clinical-radiomics models) were developed to predict recurrence based on logistic regression.

RESULTS:

The clinical-radiomics model of WS showed the best performance, with the area under the curve values of 0.853 (95% confidence interval: 0.765-0.941) in training and 0.752 (0.580-0.924) in test dataset. In the analysis of radiomic feature importance of all models, among all radiomic features, glcm_MaximumProbability, shape_MeshVolume and shape_MajorAxisLength had negative coefficients. In contrast, shape_SurfaceVolumeRatio, shape_Elongation, glszm_SizeZoneNonUniformityNormalized, and gldm_GrayLevelNonUniformity had positive coefficients.

CONCLUSION:

In this study, a machine-learning model based on cone-beam CT images obtained at the completion of c-TACE was able to predict local tumor recurrence after successful c-TACE. Nonuniform lipiodol deposition and irregular shapes may increase the likelihood of recurrence.

01 Nov 2024·EBioMedicine

Gelation embolism agents suppress clinical TACE-incited pro-metastatic microenvironment against hepatocellular carcinoma progression

Article

Author: Qin, Wen ; Cao, Xin ; Zhang, Kun ; Yang, Biwei ; Song, Li ; Shi, Qing ; Zhu, Chunyan ; Ye, Tao ; Xia, Yuhan ; Liang, Xiayi ; Xia, Jinglin

BACKGROUND:

Current embolic agents in transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) encounter instability and easy leakage, discounting TACE efficacy with residual HCC. Moreover, clinical TACE aggravates hypoxia and pro-metastatic microenvironments, rendering patients with HCC poor prognosis.

METHODS:

Herein, we developed Zein-based embolic agents that harness water-insoluble but ethanol-soluble Zein to encompass doxorubicin (DOX)-loaded mesoporous hollow MnO₂ (HMnO₂). The conditions and capacity of HMnO₂ to generate reactive oxygen species (ROS) were assayed. Mechanical examinations of Zein-HMnO₂@DOX were performed to evaluate its potential as the embolic agent. In vitro experiments were carried out to evaluate the effect of Zein-HMnO₂@DOX on HCC. The subcutaneous HCC mouse model and rabbit VX2 HCC model were established to investigate its anti-tumor and anti-metastasis efficacy and explore its potential anti-tumor mechanism.

FINDINGS:

The high adhesion and crosslinking of Zein with HMnO₂@DOX impart Zein-HMnO₂@DOX with strong mechanical strength to resist deformation and wash-off. Zein gelation and HMnO₂ decomposition in response to water and acidic tumor microenvironment, respectively, enable continuous DOX release and Fenton-like reaction for reactive oxygen species (ROS) production and O₂ release to execute ROS-enhanced TACE. Consequently, Zein-based embolic agents outperform clinically-used lipiodol to significantly inhibit orthotopic HCC growth. More significantly, O₂ release down-regulates hypoxia inducible factor (HIF-1α), vascular endothelial growth factor (VEGF) and glucose transporter protein 1 (GLUT1), which thereby re-programmes TACE-aggravated hypoxic and pro-metastatic microenvironments to repress HCC metastasis towards lung. Mechanistic explorations uncover that such Zein-based TACE agents disrupt oxidative stress, angiogenesis and glycometabolism pathways to inhibit HCC progression.

INTERPRETATION:

This innovative work not only provides a new TACE agent for HCC, but also establishes a new strategy to ameliorate TACE-aggravated hypoxia and metastasis motivation against clinically-common HCC metastasis after TACE operation.

FUNDING:

Excellent Young Science Fund for National Natural Science Foundation of China (82022033); National Natural Science Foundation of China (Grant No. 82373086, 82102761); Major scientific and technological innovation project of Wenzhou Science and Technology Bureau (Grant No. ZY2021009); Shanghai Young Top-Notch Talent.

News (Medical) associated with Ethiodized Oil

24 Oct 2024

·www.globenewswire.com

GUERBET : Revenue at September 30, 2024.

Revenue at September 30, 2024 Continued growth momentum 9-month revenue: €620.5m, up 9.6% at CER1 In the third quarter, momentum remained strong (+5.4% at CER), driven by the Americas (+13.1%) and Asia (+8.1%), while performance in EMEA (-2.3%) was once again impacted by the continued implementation of the new supply chain in France 2024 annual targets confirmed Revenue: expected growth of over 9%on a like-for-like basis and at CERProfitability: re-stated EBITDA margin returnedto a higher level than in 2021 (14.4%) Villepinte, October 24, 2024, 5:45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast products and solutions for medical imaging, is publishing its revenue as at September 30, 2024. In the first nine months of the financial year, Group sales reached 620.5 million euros (€m), up 8.1% compared with the same period in 2023. This performance includes an unfavorable currency effect of €8.6m, mainly due to the depreciation of the Japanese yen and the Brazilian real. At constant exchange rates (CER1), Guerbet's revenue growth was 9.6% as at September 30, 2024. In the third quarter alone, sales were up 3.1% to €201.3m. At CER, growth was 5.4% over the period. Geographical breakdown of the Group's consolidated revenue (IFRS) In thousands of euros,at September 30, 20249 months 20239 months 2024% change9 months 2024at CER1% changeat CEREMEA sales258.5261.6+1.2%261.0+1.0%Americas sales160.9194.3+20.7%197.8+22.9%Asia sales154.4164.7+6.6%170.4+10.3%Total573.9620.5+8.1%629.1+9.6% At constant exchange rates: the impact of exchange rates was eliminated by recalculating sales for the period based on the exchange rates used for the previous year. In EMEA, the Group's revenue totaled €261.6m in the first nine months of the financial year, up 1.0% at CER despite the decline in sales in France. On this market, following the reform of the supply chain for contrast products on March 1, 2024, there has been an erratic trend in sales linked to the implementation of a new management system for flows between distributors and radiologists. These disruptions particularly affected activity in the third quarter, with EMEA down 2.3% at CER. In the Americas, sales at end-September 2024 were up 22.9% at CER to €194.3m. This momentum, fueled by the increase in both volumes and prices, was characterized by an outstanding performance in Latin America. In the third quarter, sales in the Americas were up 13.1%, following three quarters of exceptional growth (>20%) linked to the recovery at the Raleigh site. In Asia, 9-month sales reached €164.7m, up 10.3% at CER despite the contraction in activity in South Korea (-4.8%), which has been affected by a doctors' strike since February. In the third quarter alone, growth was 8.1% at CER, underpinned by very favorable momentum in China (+24.2% over the period). Breakdown of the Group's consolidated revenue by activity (IFRS) In thousands of euros,at September 30, 20249 months 20239 months 2024% change9 months 2024at CER1% changeat CERDiagnostic Imaging 506.4546.4+7.9%554.0+9.4%MRI187.3191.8+2.4%193.1+3.1%X-ray319.0354.6+11.2%360.9+13.1%Interventional Imaging67.574.1+9.9%75.1+11.3%Total573.9620.5+8.1%629.1+9.6% At constant exchange rates: the impact of exchange rates was eliminated by recalculating sales for the period based on the exchange rates used for the previous year. Sales at CER for the Diagnostic Imaging business were up 9.4% at September 30, 2024 and +6.9% in the third quarter. In the MRI division, 9-month revenue increased by 3.1% at CER, including a slight decline in the third quarter of 2024 (-1.1%). This change is the direct consequence of the temporary difficulties encountered on the French market, which particularly affected sales of Dotarem®. Revenue for the X-ray division reached €354.6m at September 30, 2024, up 13.1% at CER. Performance in the third quarter (+11.6%) was underpinned by continued strong sales of Xenetix® and in particular Optiray®. In Interventional Imaging, activity at CER was up 11.3% compared to the first nine months of 2023, thanks to strong sales of Lipiodol® in terms of both volumes and prices. The change in the third quarter alone (-4.6% at CER) is not significant from a full-year perspective. Confirmation of financial targets for 2024 In the wake of these first nine months marked by strong trends across the entire product portfolio and in the main geographical areas, except occasionally in France, Guerbet expects to continue positive momentum in the fourth quarter. In this context, the Group confirms that it is targeting sales growth of over 9% on a like-for-like and CER basis for 2024, as well as a restated EBITDA margin rate higher than that recorded in 2021 (14.4%). Next event: Publication of 2024 annual sales 6 February 2025 after market close About GuerbetAt Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 97 years, with more than 2,920 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, the United States and Israel. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €786 million in revenue in 2023. Forward-looking statementsCertain information contained in this press release does not reflect historical data but constitutes forward-looking statements. These forward-looking statements are based on estimates, forecasts, and assumptions, including but not limited to assumptions about the current and future strategy of the Group and the economic environment in which the Group operates. They involve known and unknown risks, uncertainties, and other factors that may result in a significant difference between the Group’s actual performance and results and those presented explicitly or implicitly by these forward-looking statements.These forward-looking statements are valid only as of the date of this press release, and the Group expressly disclaims any obligation or commitment to publish an update or revision of the forward-looking statements contained in this press release to reflect changes in their underlying assumptions, events, conditions, or circumstances. The forward-looking statements contained in this press release are for illustrative purposes only. Forward-looking statements and information are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and are generally beyond the Group’s control. These risks and uncertainties include but are not limited to the uncertainties inherent in research and development, future clinical data and analyses (including after a marketing authorization is granted), decisions by regulatory authorities (such as the US Food and Drug Administration or the European Medicines Agency) regarding whether and when to approve any application for a drug, process, or biological product filed for any such product candidates, and their decisions regarding labeling and other factors that may affect the availability or commercial potential of such product candidates. A detailed description of the risks and uncertainties related to the Group’s activities can be found in Chapter 4.9 “Risk factors” of the Group’s Universal Registration Document filed with the AMF (French financial markets authority) under number D.24-0224 on April 3, 2024, available on the Group’s website (www.guerbet.com). 1 At constant exchange rates: the impact of exchange rates was eliminated by recalculating sales for the period based on the exchange rates used for the previous financial year.2 Excluding exceptional costs related to the optimization of the operational framework and changes to the sales model. Contacts: Guerbet Jérôme Estampes, Chief Financial Officer +33 1 45 91 50 00 / jerome.estampes@guerbet.comChristine Allard, Head of Communications +33 6 30 11 57 82 / christine.allard@guerbet.com Seitosei Actifin Marianne Py, Financial Communications +33 1 80 48 25 31 / marianne.py@seitosei-actifin.com Jennifer Jullia, Press +33.1.56.88.11.19 / jennifer.jullia@seitosei-actifin.com Attachment 24 10-24 CP GBT CA T3 VDef EN

Financial Statement

25 Jul 2024

·www.globenewswire.com

GUERBET : H1 2024 revenue.

H1 2024 revenue Half-yearly activity H1 revenue: €419.2m, up 11.8% at CER1, including an acceleration in Q2 (+14.5%)This acceleration was driven by continued catch-up in the Americas, the normalisation of orders in France and MRI sales Annual targets confirmed Revenue: expected growth of over 8% like-for-like and at CERProfitability: restated EBITDA margin rate2 higher than in 2021 (14.4%) Villepinte, 25 July 2024, 5.45 pm: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is publishing its revenue for first-half 2024. As of June 30th, 2024, the Group’s sales totalled €419.2m, up 10.7% compared with the same period in 2023 (€378.6m). Earnings reflected a negative forex effect of €4.1m. At constant exchange rates (CER1), Guerbet’s growth over the first six months was 11.8%. This trend includes an acceleration in the second quarter (+14.5% at CER), following what was already a highly positive momentum in the first quarter (+8.8%). Geographical breakdown of consolidated Group revenue (IFRS) In millions of euros,at 30 June 2024H1 2023*H1 2024% changeH1 2024At CER1% changeSales in EMEA178.5183.4+2.7%182.8+2.4%Sales in the Americas98.6127.3+29.2%127.2+29.1%Sales in Asia101.5108.5+6.8%113.2+11.5%Total378.6419.2+10.7%423.3+11.8% In the EMEA region, Group revenue amounted to €183.4m in the first half, up 2.4% at CER. The decline in the first quarter (-6.2% at CER) was fully offset in the second (+11.0% at CER) as business returned to normal in France after the disruptions linked to the March 1st 2024 reform of the supply circuit for contrast products. Guerbet revenue in the Americas caught up strongly for the third consecutive quarter, with growth of 37.4% in the second quarter at CER, reflecting record production levels at the Raleigh site in North Carolina. Total H1 revenue in the Americas came out at €127.3m, up 29.1% at CER. Asia posted growth of 6.8% over the period, at €108.5m, including a persistent negative currency effect. At CER, growth totalled 11.5% in the first half, despite a slowdown in the second quarter stemming from the contraction in sales in South Korea, where access to care has been paralysed since mid-February by an unprecedented doctor strike. Breakdown of consolidated Group revenue (IFRS) by activity In millions of euros,at 30 June 2024H1 2023*H1 2024% changeH1 2024At CER1% changeDiagnostic Imaging 336.5368.8+9.6%372.3+10.7%MRI125.0131.1+4.8%131.5+5.2%X-ray211.4237.7+12.4%240.8+13.9%Interventional Imaging42.250.4+19.5%50.9+20.8%Total378.6419.2+10.7%423.3+11.8% Diagnostic Imaging revenue amounted to €368.8m in H1 2024, up 10.7% at CER. MRI sales increased 5.2% at CER in the first half of the year thanks to a solid performance in the second quarter (+13.5%). Over this period, business was driven by a strong performance by the MRI franchise, and particularly the development of EluciremTM in the United States, together with the initial sales in Germany. X-ray revenue grew 13.9% at CER in H1 2024 as part of a positive business dynamic fuelled by sales of Xenetix® and Optiray®. In Interventional Imaging, revenue at mid-year was up 20.8% at CER. This remarkable performance reflects a strong pick-up in the second quarter (+33.8% at CER) on continued positive momentum for Lipiodol®, in terms both of volumes and prices. Solid visibility for H2 - Confirmation of financial targets for 2024 Having achieved a sustained growth trajectory in the first half of the year, Guerbet enters the second half in full peace of mind. Beyond the catch-up in sales in the Americas, business continues to benefit from firmly established growth drivers firmly across the entire portfolio: in X-rays (Optiray® in particular), Interventional Imaging (strong momentum with Lipiodol®) and the MRI franchise. The latter is now reinforced by the expansion in Europe of EluciremTM, which, after receiving an extremely favourable reception in Germany in Q2 2024, will be launched in in the UK and France in the second half. Guerbet also remains confident in improving its operating profitability, driven by the adjustment of the product mix and price increases, and in its ability to bring cash generation into positive territory. Given these circumstances, the Group is confirming its forecast of sales growth of over 8% in 2024 like-for-like and at CER and expects its adjusted EBITDA margin rate to exceed that of 2021 (14.4%). Free cash flow is expected to be in positive territory for the full year. Next event: Publication of 1st half 2024 results 25 September 2024 after market close About GuerbetAt Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 97 years, with more than 2,920 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, the United States and Israel. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €786 million in revenue in 2023. Forward-looking statementsCertain information contained in this press release does not reflect historical data but constitutes forward-looking statements. These forward-looking statements are based on estimates, forecasts, and assumptions, including but not limited to assumptions about the current and future strategy of the Group and the economic environment in which the Group operates. They involve known and unknown risks, uncertainties, and other factors that may result in a significant difference between the Group’s actual performance and results and those presented explicitly or implicitly by these forward-looking statements.These forward-looking statements are valid only as of the date of this press release, and the Group expressly disclaims any obligation or commitment to publish an update or revision of the forward-looking statements contained in this press release to reflect changes in their underlying assumptions, events, conditions, or circumstances. The forward-looking statements contained in this press release are for illustrative purposes only. Forward-looking statements and information are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and are generally beyond the Group’s control. These risks and uncertainties include but are not limited to the uncertainties inherent in research and development, future clinical data and analyses (including after a marketing authorization is granted), decisions by regulatory authorities (such as the US Food and Drug Administration or the European Medicines Agency) regarding whether and when to approve any application for a drug, process, or biological product filed for any such product candidates, and their decisions regarding labeling and other factors that may affect the availability or commercial potential of such product candidates. A detailed description of the risks and uncertainties related to the Group’s activities can be found in Chapter 4.9 “Risk factors” of the Group’s Universal Registration Document filed with the AMF (French financial markets authority) under number D.24-0224 on April 3, 2024, available on the Group’s website (www.guerbet.com). 1 Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year.2 Restated EBITDA margin rate: excluding non-recurring costs related to the optimisation of the operating plan and changes in the sales model. Contacts: Guerbet Jérôme Estampes, Chief Financial Officer +33 1 45 91 50 00 / jerome.estampes@guerbet.comChristine Allard, Head of Communications +33 6 30 11 57 82 / christine.allard@guerbet.com Actifin Marianne Py, Financial Communications +33 1 80 48 25 31 / marianne.py@seitosei-actifin.com Jennifer Jullia, Press +33.1.56.88.11.19 / jennifer.jullia@seitosei-actifin.com Attachment 24 07-25 CP Guerbet CA S1 2024 VDef EN

Financial StatementBiosimilar

25 Apr 2024

·www.globenewswire.com

Guerbet : Q1 2024 revenue.

Q1 2024 revenue Quarterly activity Revenue: €194.3m, up 8.8% at CER1Growth remains particularly strong in Asia (+26.8% at CER) and the Americas (+20.1% at CER); the EMEA region (-6.2% at CER) was temporarily impacted by the reform of the supply of contrast products in France Annual targets confirmed Revenue: expected growth of over 8% like-for-like and at CERProfitability: restated EBITDA margin rate2 higher than in 2021 (14.4%) Villepinte, 25 April 2024, 5.45 pm: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is publishing its revenue for the first fiscal quarter. At 31 March 2024, the Group’s sales totalled €194.3m, up 7.6% compared with the same period in 2023. Given an unfavourable foreign exchange effect of €2.2m, largely linked to Asian currencies, revenue at CER1 was up 8.8% over the period. Geographical breakdown of consolidated Group revenue (IFRS) In millions of euros,at 31 March 2024Q1 2023*Q1 2024% changeQ1 2024At CER1% changeSales in EMEA89.083.9-5.8%83.6-6.2%Sales in the Americas47.557.4+21%57.0+20.1%Sales in Asia44.152.9+20%55.9+26.8%Total180.6194.3+7.6%196.5+8.8% *Revenue for Q1 2023 has been restated to include Intrasense, which has been consolidated since 1 January 2023. In the EMEA region, the Group generated revenue of €83.9m in the first quarter, down 5.8% (-6.2% at CER) mainly owing to the dip in sales volumes in France. This trend stems directly from the implementation on 1 March 2024 of the reform of the supply circuit for contrast products, which caused difficulties in order intakes with radiologists. The Group expects to largely catch up on the resulting delays in sales in the second quarter of 2024. In the Americas, sales totalled €57.4m, up 21.0% over the period (+20.1% at CER). Sales caught up strongly for the second consecutive quarter following the return to historic production levels at the Raleigh site in North Carolina. Group revenue in Asia was €52.9m, with continued strong growth momentum (+20%) driven by the performances of China, South Korea and Japan. The total includes a negative currency effect (-€3.0m) linked in particular to the further depreciation of the yen. At CER, sales in Asia rose 26.8% in first-quarter 2024, confirming the Group’s ambitions in this region. Breakdown of consolidated Group revenue (IFRS) by activity In millions of euros,at 31 March 2024Q1 2023*Q1 2024% changeQ1 2024At CER1% changeDiagnostic Imaging 160.8173.6+7.9%175.5+9.1%MRI60.758.2-4.1%58.4-3.7%X-ray100.2115.4+15.2%117.1+16.9%Interventional Imaging19.820.7+4.4%21.0+6.1%Total180.6194.3+7.6%196.5+8.8% 1 Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year.*Revenue for Q1 2023 has been restated to include Intrasense, which has been consolidated since 1 January 2023. Diagnostic Imaging revenue increased 7.9% in Q1 2024 (+9.1% at CER) to €173.6m. MRI activity was down 3.7% at CER. This decline resulted from the postponement of several substantial orders in the MRI franchise (Dotarem® / EluciremTM) in France, all of which will be booked in the second quarter of 2024.X-ray revenue increased 16.9% at CER over the period, a remarkable increase driven by all the division’s products, particularly Xenetix®. In Interventional Imaging, revenue rose 6.1% at CER in Q1 2024 on continued favourable momentum for Lipiodol®, fuelled by volumes and prices alike. All financial targets confirmed for 2024 The highly positive trend overall at the start of the year boosts Guerbet’s confidence for the full year. In a buoyant contrast products market, Group business will be bolstered by the ramp-up of the MRI franchise, growth in Optiray® sales, and continued favourable momentum for Lipiodol®. At the same time, operating profitability will benefit from the change in the product mix and the continued rise in prices, while cash generation will improve considerably, particularly as inventory levels return to normal. Given these circumstances, Guerbet is confirming its forecast of sales growth of over 8% in 2024 like-for-like and at CER and expects its adjusted EBITDA margin rate to exceed that of 2021 (14.4%). Free cash flow is expected to be in positive territory for the full year. Next events : Annual Shareholders' Meeting for fiscal year 202324 May 2024 Publication of 1st half 2024 revenue 25 July 2024 after market close About GuerbetAt Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 97 years, with more than 2,920 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, the United States and Israel. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €786 million in revenue in 2023. Forward-looking statementsCertain information contained in this press release does not reflect historical data but constitutes forward-looking statements. These forward-looking statements are based on estimates, forecasts, and assumptions, including but not limited to assumptions about the current and future strategy of the Group and the economic environment in which the Group operates. They involve known and unknown risks, uncertainties, and other factors that may result in a significant difference between the Group’s actual performance and results and those presented explicitly or implicitly by these forward-looking statements.These forward-looking statements are valid only as of the date of this press release, and the Group expressly disclaims any obligation or commitment to publish an update or revision of the forward-looking statements contained in this press release to reflect changes in their underlying assumptions, events, conditions, or circumstances. The forward-looking statements contained in this press release are for illustrative purposes only. Forward-looking statements and information are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and are generally beyond the Group’s control. These risks and uncertainties include but are not limited to the uncertainties inherent in research and development, future clinical data and analyses (including after a marketing authorization is granted), decisions by regulatory authorities (such as the US Food and Drug Administration or the European Medicines Agency) regarding whether and when to approve any application for a drug, process, or biological product filed for any such product candidates, and their decisions regarding labeling and other factors that may affect the availability or commercial potential of such product candidates. A detailed description of the risks and uncertainties related to the Group’s activities can be found in Chapter 4.9 “Risk factors” of the Group’s Universal Registration Document filed with the AMF (French financial markets authority) under number D.24-0224 on April 3, 2024, available on the Group’s website (www.guerbet.com). 1 Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year.2 Restated EBITDA margin rate : excluding non-recurring costs related to the optimisation of the operating plan and changes in the sales model. Attachment CP CA T1 2024_VFinale EN

Financial Statement

100 Deals associated with Ethiodized Oil

External Link

KEGG	Wiki	ATC	Drug Bank
D04082	Ethiodized Oil	V09	DB00965

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hepatocellular Carcinoma	US	Guerbet LLC	04 Apr 2014
Liver Cancer	CA	Guerbet SA	31 Dec 1977
Contrast agents	US	Guerbet LLC	31 Mar 1954

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03370575 (Pubmed)	Phase 4	Contrast agents	1,026	Ethiodized poppyseed oil	vklycvrbgn(bfyrejzchy) = ouolmpjcki uxfcmrkgnb (qkhfaouujb )	Positive	01 Apr 2022
NCT03370575 (Pubmed)	Phase 4	Contrast agents	1,026	Ethiodized poppyseed oil-based contrast medium	vklycvrbgn(bfyrejzchy) = ecgktctvgd uxfcmrkgnb (qkhfaouujb )	Positive	01 Apr 2022
NCT03604549 (CTgov)	Phase 4	Infertility	58	Saline (Saline)	zidlytxycv(vhgtiupdeh) = mxfsxpkgln lriptvnnaz (btyrebvkzq, dhxznmqbjx - oqgcmudjxv) View more	-	24 Feb 2022
NCT03604549 (CTgov)	Phase 4	Infertility	58	Lipiodol UF (Lipiodol UF)	zidlytxycv(vhgtiupdeh) = erpeqyiwmw lriptvnnaz (btyrebvkzq, yzjfnnbjvq - gerlzanfdp) View more	-	24 Feb 2022
NCT01877187 (CTgov)	Phase 2	Liver metastases \| Liver Cancer	39	lipiodol	frbnbrcvkx(euikgxrzcv) = twgtixhhwa acxnxvouxm (dfkhscgfmi, qpnjowwxxa - vxxwhhwldm)	-	15 Apr 2020
ASCO2012	Not Applicable	Advanced Hepatocellular Carcinoma	15	I-131-lipiodol	tsqcxtwkep(nnpaqeegyv) = ededuijhoq ijdjmmoxfq (jpvnwyrwnt )	Positive	20 May 2012
ASCO_GI2011	Phase 2	Unresectable Hepatocellular Carcinoma	20	Segmental or subsegmental transcatheter arterial chemoembolization using cisplatin powder mixed with ethiodized oil	(oqzhpzdstt) = djdvvxmddm gxmnasvjrg (xctteyfyze, 5.25 - 29.9) View more	Positive	01 Feb 2011
Pubmed \| Acta Oncol	Not Applicable	Bladder Cancer	5	Lipiodol injection	qxvskshwts(wfiioptdjp) = dtegkbbguc bowwegtbbz (eehgewkozg )	-	01 Oct 2010
ASCO2005	Not Applicable	Liver metastases	43	Lipiodol I131 + Oxaliplatin + FUDR + LV	ntbgfhyvyv(pfvihgwysu) = mjdukvtxyq tqfzxbehzq (lvycyjghfv )	-	01 Jun 2005
Pubmed \| J Nutr	Not Applicable	Iodine deficiency	305	Lipiodol	lyokliwbus(bvbnrpzvso) = pzxsqbayrv naozyxccqq (emekbmmlnv )	-	01 Jan 2001

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ethiodized Oil

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation